Statin use and the risk of Parkinson disease - PubMed (original) (raw)

Comparative Study

Statin use and the risk of Parkinson disease

Angelika D Wahner et al. Neurology. 2008.

Abstract

Objective: To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).

Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.

Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.

Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors report no conflicts on interest.

Cited by

Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S, Raymick J, Imam S. Sarkar S, et al. Int J Mol Sci. 2016 Jun 8;17(6):904. doi: 10.3390/ijms17060904. Int J Mol Sci. 2016. PMID: 27338353 Free PMC article. Review.
Prospective study of statin use and risk of Parkinson disease.
Gao X, Simon KC, Schwarzschild MA, Ascherio A. Gao X, et al. Arch Neurol. 2012 Mar;69(3):380-4. doi: 10.1001/archneurol.2011.1060. Arch Neurol. 2012. PMID: 22410446 Free PMC article.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
Willey JZ, Elkind MS. Willey JZ, et al. Arch Neurol. 2010 Sep;67(9):1062-7. doi: 10.1001/archneurol.2010.199. Arch Neurol. 2010. PMID: 20837848 Free PMC article. Review.
The Effect of Oral Simvastatin on the Clinical Outcome of Patients with Severe Traumatic Brain Injury: A Randomized Clinical Trial.
Shafiee S, Zali A, Shafizad M, Emami Zeydi A, Ehteshami S, Rezaii F, Tafakhori A, Ertiaei A, Darvishi-Khezri H, Khademloo M, Khoshnood RJ. Shafiee S, et al. Ethiop J Health Sci. 2021 Jul;31(4):807-816. doi: 10.4314/ejhs.v31i4.15. Ethiop J Health Sci. 2021. PMID: 34703180 Free PMC article. Clinical Trial.
Prospects of statins in Parkinson disease.
Roy A, Pahan K. Roy A, et al. Neuroscientist. 2011 Jun;17(3):244-55. doi: 10.1177/1073858410385006. Epub 2011 Jan 20. Neuroscientist. 2011. PMID: 21252380 Free PMC article. Review.

References

1. Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, Co-enzyme Q10, and Parkinson’s disease. Parkinsonism Relat Disord. 2005;11:81–84. - PubMed
1. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S13. - PubMed
1. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18:101–11. Review. - PubMed
1. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord. 2006 Dec 18; Epub ahead of print. - PMC - PubMed
1. de Lau LM, Koudstall PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006;164:998–1002. - PubMed

Statin use and the risk of Parkinson disease - PubMed (original) (raw)